FR2353641A1 - Vaccin anti-tumoral et son procede de preparation - Google Patents

Vaccin anti-tumoral et son procede de preparation

Info

Publication number
FR2353641A1
FR2353641A1 FR7716547A FR7716547A FR2353641A1 FR 2353641 A1 FR2353641 A1 FR 2353641A1 FR 7716547 A FR7716547 A FR 7716547A FR 7716547 A FR7716547 A FR 7716547A FR 2353641 A1 FR2353641 A1 FR 2353641A1
Authority
FR
France
Prior art keywords
preparation process
tumor vaccine
vaccine
tumor
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7716547A
Other languages
English (en)
Other versions
FR2353641B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of FR2353641A1 publication Critical patent/FR2353641A1/fr
Application granted granted Critical
Publication of FR2353641B1 publication Critical patent/FR2353641B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
FR7716547A 1976-06-01 1977-05-31 Vaccin anti-tumoral et son procede de preparation Granted FR2353641A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/691,486 US4108983A (en) 1976-06-01 1976-06-01 Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors

Publications (2)

Publication Number Publication Date
FR2353641A1 true FR2353641A1 (fr) 1977-12-30
FR2353641B1 FR2353641B1 (fr) 1980-07-18

Family

ID=24776726

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7716547A Granted FR2353641A1 (fr) 1976-06-01 1977-05-31 Vaccin anti-tumoral et son procede de preparation

Country Status (8)

Country Link
US (1) US4108983A (fr)
JP (1) JPS52148617A (fr)
AU (1) AU511071B2 (fr)
CA (1) CA1073814A (fr)
DE (1) DE2705610A1 (fr)
FR (1) FR2353641A1 (fr)
GB (1) GB1520200A (fr)
NZ (1) NZ182891A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037441A1 (fr) * 1980-03-10 1981-10-14 Seiji Arakawa Compositions pharmaceutiques utilisables comme immunostimulant cellulaire et comme agent anti-tumeur, procédé de préparation et microorganisme utilisé
WO1990011765A1 (fr) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Preparation antitumorale obtenue apres traitement d'un oncolysat

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835121A (ja) * 1981-08-20 1983-03-01 ビラス・ヴィー・リクハイト 免疫刺激性補助剤からなる抗原及び免疫療法におけるその使用
US4652522A (en) * 1983-07-05 1987-03-24 The University Of Pennsylvania Continuous lymphocyte cell lines, their production and use
JPS6038328A (ja) * 1983-08-11 1985-02-27 Handai Biseibutsubiyou Kenkyukai 抗腫瘍免疫誘導の増強法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US6338853B1 (en) 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
ES2196026T3 (es) * 1993-04-30 2003-12-16 Wellstat Biologics Corp Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
MXPA01010393A (es) * 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
AU2007215328A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
JP5944901B2 (ja) 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
US9623096B2 (en) 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553312A (en) * 1968-02-26 1971-01-05 Flow Lab Process for producing rubella-virus hemagglutinating antigen

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037441A1 (fr) * 1980-03-10 1981-10-14 Seiji Arakawa Compositions pharmaceutiques utilisables comme immunostimulant cellulaire et comme agent anti-tumeur, procédé de préparation et microorganisme utilisé
WO1990011765A1 (fr) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Preparation antitumorale obtenue apres traitement d'un oncolysat

Also Published As

Publication number Publication date
JPS52148617A (en) 1977-12-10
AU511071B2 (en) 1980-07-24
DE2705610A1 (de) 1977-12-15
GB1520200A (en) 1978-08-02
US4108983A (en) 1978-08-22
CA1073814A (fr) 1980-03-18
DE2705610C2 (fr) 1989-08-03
NZ182891A (en) 1984-03-30
AU2173577A (en) 1978-08-03
FR2353641B1 (fr) 1980-07-18

Similar Documents

Publication Publication Date Title
FR2353641A1 (fr) Vaccin anti-tumoral et son procede de preparation
BE857931A (fr) Gel de phospha-alumine et son procede de preparation
FR2312259A1 (fr) Medicament anti-tumoral
BE849794A (fr) Derives de carbostyrile et leur procede de preparation
BE850401A (fr) Derives de phtalane et procede de preparation
FR2319383A1 (fr) Systeme de distribution de vaccin
BE858992A (fr) Procede de preparation de vaccins
BE824697A (fr) Derives de benzylamine et leur procede de preparation
SE7604818L (sv) Vaccin
FR2347933A1 (fr) Vaccin antirabique et son procede de preparation
LU79508A1 (fr) Nouveau vaccin vivant ameliore contre la pseudopeste aviaire et son procede de preparation
BE831856A (fr) Derives de benzimidazole et leur procede de preparation
FR2299032A1 (fr) Derives de tetrahydroisoquinoleine et leur procede de preparation
PT65124B (fr) Lucknomycine et son procede de preparation
FR2318652A1 (fr) Nouveau vaccin anti-rabique et son procede de preparation
IT7867143A0 (it) Vaccino e procedimento per lasua preparazione
BE827870A (fr) Derives d'emidazole et leur procede de preparation
BE830814A (fr) N-alkyl-iminoalanes oligomeres et leur procede de preparation
FR2338708A1 (fr) Vaccin contre la panleucopenie des felides et son procede de preparation
SE7813201L (sv) Vaccin
BE831786A (fr) Vaccin contre la gravidite et procede de sa preparation
BE869723A (fr) Charge fumigene et son procede de preparation
BE826139A (fr) 11beta-fluoro-androstenes et leur procede de preparation
BE826062A (fr) Derives de phenylbutanol et leur procede de preparation
FR2319377A1 (fr) Fortimicine c et son procede de preparation

Legal Events

Date Code Title Description
ST Notification of lapse